Article
Hematology
Julian Lindsay, Ian Kerridge, Leonie Wilcox, Steven Tran, Tracey A. O'Brien, Matthew Greenwood, Sharon C-A Chen, David C. M. Kong, Steven A. Pergam, Catherine Liu, Monica A. Slavin
Summary: Infection-related mortality (IRM) is the most common non-relapse-related cause of death after allogeneic hematopoietic cell transplantation (HCT). This report provides the first account of IRM in Australia, highlighting the importance of understanding specific infective organisms and risk factors for developing prevention strategies. The study identified key risk factors for IRM in adults and children undergoing HCT, emphasizing the need for personalized infection risk assessment and prevention strategies to reduce IRM.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Article
Hematology
Sara Fernandez-Luis, David Gomez Lamas, Juan Manuel Cerezo Martin, Juan Manuel Mora Barrios, Lucrecia Yanez San Segundo, Miriam Sanchez Escamilla, Noemi Fernandez-Escalada, Jose Alvaro Calvo Sanchez, Sergio Fernandez Garcia, Juan Jose Dominguez-Garcia, Mercedes Colorado Araujo, Monica Lopez-Duarte, Guillermo Martin-Sanchez, Andres Insunza Gaminde, Jose Inigo Romon Alonso, Rocio Lobeira Rubio, Jose Luis Arroyo Rodriguez, Beatriz Rueda Ciller, Mar Hermosilla Fernandez, Victor Marco Betes, Enrique Maria Ocio, Arancha Bermudez Rodriguez
Summary: This study analyzed the outcome of 97 patients older than 60 years who underwent their first allogeneic transplantation. The results showed that there were no significant differences in overall survival, progression-free survival, cumulative incidence of relapse, or non-relapse mortality between different age groups or conditioning regimens. The study suggests that older adults can safely and effectively undergo allogeneic transplantation with proper patient selection and individualized procedures.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Abel Santos Carreira, Maria Queralt Salas, Mats Remberger, Igor Novitzky Basso, Arjun Datt Law, Wilson Lam, Ivan Pasic, Dennis Kim, Fotios Michelis, Auro Viswabandya, Armin Gerbitz, Jeffrey Howard Lipton, Shahid Husain, Rajat Kumar, Jonas Mattsson
Summary: This study investigated the incidence and risk factors for bloodstream infections (BSIs) in allogeneic hematopoietic cell transplantation (alloHCT) recipients and explored their impact on post-transplantation outcomes. High Disease Risk Index and receipt of post-transplantation cyclophosphamide (PTCy) were identified as risk factors for BSI. Patients with BSI had a higher risk of mortality.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Masaaki Hotta, Atsushi Satake, Hideaki Yoshimura, Shinya Fujita, Yuta Katayama, Shuichi Ota, Hitoshi Hanamoto, Tatsuo Oyake, Shigeki Ito, Masaya Okada, Takahisa Nakanishi, Tomoki Ito, Kazuyoshi Ishii, Shosaku Nomura
Summary: Early prediction of nonrelapse mortality (NRM) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) is challenging. Using plasma biomarkers ST2 and Reg3 alpha, along with the MAGIC algorithm, can help identify individuals at high risk for NRM. By analyzing blood samples and calculating risk scores, patients can be categorized into low-risk and high-risk groups for predicting the cumulative incidence of 6-month NRM.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Article
Immunology
Yuanfeng Zhang, Xin Chen, Donglin Yang, Aiming Pang, Rongli Zhang, Qiaoling Ma, Weihua Zhai, Yi He, Jialin Wei, Erlie Jiang, Mingzhe Han, Sizhou Feng
Summary: This study conducted a retrospective cohort analysis on patients with severe aplastic anemia (SAA) who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) to compare their survival between those with infection and those without infection. The study found that patients with infection before transplantation had inferior survival compared to those without infection, highlighting the importance of prophylaxis and complete control of infectious complications before transplantation among SAA patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Lijie Han, Haiyan Zhang, Ping Ma, Jie Peng, Yilu Li, Jiaying Wu, Yuanyuan Li, Jifeng Yu, Wei Li, Mengmeng Zhang, Jia Bao He, Zhiping Fan, Weimin Wang, Li'na Sang, Hui Sun, Qifa Liu, Yang Liu, Zhongxing Jiang
Summary: The intestinal microbiota score at neutrophil recovery could predict survival following allo-HSCT. A low score was associated with better 3-year cumulative overall survival and lower mortality. High score was found to be an independent risk factor for poor survival.
ANNALS OF HEMATOLOGY
(2022)
Article
Hematology
Hiroyuki Kubo, Osamu Imataki, Tetsuya Fukumoto, Maki Oku, Tomoya Ishida, Yukiko Hamasaki Kubo, Jun-ichiro Kida, Makiko Uemura, Haruyuki Fujita, Hirofumi Ohno, Makoto Ide, Hiroaki Ohnishi, Norimitsu Kadowaki
Summary: The study revealed that risk factors for PE varied over time post-transplant, and the development of whole-circumference PE was associated with lower overall survival and higher nonrelapse mortality rates in patients.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Article
Immunology
Anna Soderstrom, Sofie Vonlanthen, Kerstin Jonsson-Videsater, Stephan Mielke, Hannes Lindahl, Johan Torlen, Michael Uhlin
Summary: This study found that measuring TREC levels can predict the prognosis of adult AML patients after bone marrow transplantation, especially overall survival. Lower TREC levels were associated with viral infections and CMV reactivation. KREC levels were not associated with clinical outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Jochen J. Frietsch, Sarah Flossdorf, James F. Beck, Nicolaus Kroeger, Katharina Fleischhauer, Peter Dreger, Johannes Schetelig, Martin Bornhaeuser, Andreas Hochhaus, Inken Hilgendorf
Summary: This retrospective analysis examined the outcomes of young adults who underwent allogeneic haematopoietic stem cell transplantation (HSCT) in Germany. The study found that the outcomes of young adults after HSCT improved over time and were influenced by factors such as underlying disease, age at disease onset, stem cell source, and donor type. However, the survival rate of HSCT recipients after 10 years was significantly lower compared to the general population of young adults.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Seom Gim Kong, Seri Jeong, Sangjin Lee, Jee-Yeong Jeong, Da Jung Kim, Ho Sup Lee
Summary: The study revealed that the cumulative incidence rates of early TRM at 50 and 100 days were 2.9% and 8.3% respectively. Predictable factors for early TRM included age, time from diagnosis to transplantation, number of prior transplantations, graft source, and previous iron chelation therapy.
Article
Hematology
Aldo A. Acosta-Medina, Anmol Baranwal, Isla McKerrow Johnson, Mohamed A. Kharfan-Dabaja, Hemant Murthy, Jeanne M. Palmer, Lisa Sproat, Abhishek Mangaonkar, Mithun V. Shah, William J. Hogan, Mark R. Litzow, Ayalew Tefferi, Hassan B. Alkhateeb
Summary: Allogeneic stem cell transplantation (alloSCT) is the curative treatment for myelofibrosis (MF). This study evaluated the predictive performance of different risk assessment tools, including HCT-CI, aHCT-CI, and EASIX, in determining nonrelapse mortality (NRM) in MF patients undergoing alloSCT.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Lars Klingen Gjaerde, Sisse Rye Ostrowski, Frederikke Schierbeck, Niels Smedegaard Andersen, Lone Smidstrup Friis, Brian Kornblit, Soren Lykke Petersen, Ida Schjodt, Henrik Sengelov
Summary: This study found that plasma ST2 levels measured before allogeneic hematopoietic cell transplantation (HCT) were associated with 1-year nonrelapse mortality (NRM) and provided additional prognostic value. The study also confirmed the associations between post-transplantation ST2 levels and outcomes of HCT. Pretransplantation ST2 levels were correlated with patient characteristics and other plasma biomarkers. ST2 levels at different time points were prognostic of 1-year NRM, all-cause mortality, relapse, and acute GVHD.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Oncology
Sang Hoon Yeon, Myung-Won Lee, Pham Thi Thuy Duong, Sora Kang, Sungju Jee, So-Young Ahn, Hyewon Ryu, Hyo-Jin Lee, Jung Hye Kwon, Hwan-Jung Yun, Deog-Yeon Jo, Ik-Chan Song
Summary: The composite HCT-CI/CPET score can predict the survival and mortality of patients with hematological malignancies who undergo allogeneic HSCT.
INTEGRATIVE CANCER THERAPIES
(2022)
Article
Oncology
Qingyuan Wang, Na Xu, Yu Wang, Xi Zhang, Limin Liu, Huifen Zhou, Hong Wang, Xiang Zhang, Xiaowen Tang, Chengcheng Fu, Miao Miao, Depei Wu
Summary: The findings of the study indicate that allo-SCT combined with MSC transfusion may represent an effective treatment option for primary myelofibrosis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Catherina Lueck, Victoria Panagiota, Elke Dammann, Razif Gabdoulline, Dominik Berliner, Christian Veltmann, Michael Heuser, Gernot Beutel, Arnold Ganser, Matthias Eder
Summary: This study investigated the occurrence of atrial fibrillation (AF) during hospitalization for allogeneic stem cell transplantation (SCT) and its impact on long-term outcomes of patients. It was found that AF had a negative impact on long-term survival rates of patients, with the main cause of death being sepsis.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Biophysics
Sebastian Giebel, Myriam Labopin, Mohamed Houhou, Denis Caillot, Juergen Finke, Didier Blaise, Nathalie Fegueux, Mark Ethell, Jan J. Cornelissen, Edouard Forcade, Ibrahim Yakoub-Agha, Federico Lussana, Johan Maertens, Jean Henri Bourhis, Pavel Jindra, Norbert Claude Gorin, Arnon Nagler, Mohamad Mohty
Summary: For elderly patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1), autologous hematopoietic cell transplantation (auto-HCT) may be considered as an alternative to reduced intensity conditioning allogeneic HCT (RIC-allo-HCT). A retrospective study compared outcomes of RIC-allo-HCT from matched sibling donors (MSD) or matched unrelated donors (MUD) with auto-HCT for patients aged 55 years or more. While the probabilities of leukemia-free survival (LFS) and overall survival (OS) were not significantly different between RIC-allo-HCT and auto-HCT, the risk of non-relapse mortality (NRM) was higher for both MSD-HCT and MUD-HCT, and for MUD-HCT, the chance of LFS and OS was lower.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
Tamim Alsuliman, Nicolas Stocker, Elise Corre, Remy Dulery, Simona Sestili, Laure Ricard, Florent Malard, Mohamad Mohty, Paul Coppo, Zora Marjanovic
Summary: Patients with high-risk lymphoma received R-COPADM and CYVE treatment, followed by ASCT if suitable. The study showed the efficacy and acceptable safety profile of this regimen, with a 87% overall survival rate and a 83% progression-free survival rate at 46 months of follow-up. These results suggest the potential benefit of this treatment approach for high-risk lymphoma patients.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Hematology
Dai Chihara, Luuk Gras, Nienke Zinger, Nicolaus Kroeger, Jiri Mayer, Jakob Passweg, Regis Peffault de Latour, Jenny Byrne, William Krueger, Jan-Paul Bohn, Uwe Platzbecker, Igor Wolfgang Blau, Francesca Bonifazi, Grzegorz Helbig, Andrew McDonald, Martin Mistrik, Mohamad Mohty, Ron Ram, Jaime Sanz, Carlos Vallejo Llamas, Robert J. Kreitman, Patrick J. Hayden, Donal McLornan, Olivier Tournilhac, Michel van Gelder, Ibrahim Yakoub-Agha
Article
Hematology
Alexandros Spyridonidis, Myriam Labopin, Bipin Savani, Sebastian Giebel, Gesine Bug, Stefan Schoenland, Nicolaus Kroeger, Matthias Stelljes, Thomas Schroeder, Andrew McDonald, Igor-Wolfgang Blau, Martin Bornhaeuser, Montse Rovira, Wolfgang Bethge, Andreas Neubauer, Arnold Ganser, Jean Henri Bourhis, Matthias Edinger, Bruno Lioure, Gerald Wulf, Kerstin Schaefer-Eckart, Mutlu Arat, Zinaida Peric, Christoph Schmid, Ali Bazarbachi, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: In this registry-based study, the outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with acute lymphoblastic leukemia (ALL) were compared. The study found that the total dose of total body irradiation (TBI) did not influence the survival outcomes for patients, regardless of whether they received a standard 12-Gray or lower 8-Gray dose.
Article
Hematology
Gerard Socie, Dietger Niederwieser, Nikolas von Bubnoff, Mohamad Mohty, Jeff Szer, Reuven Or, James Garrett, Anirudh Prahallad, Celine Wilke, Robert Zeiser
Summary: Systemic steroids are the first-line treatment for acute graft-versus-host disease, but about 50% of patients become steroid-refractory or dependent. Ruxolitinib is the only approved therapy for these patients and has shown superior efficacy compared with the best available therapy in a clinical trial.
Editorial Material
Hematology
Mohamad Mohty, Florent Malard
Summary: This study evaluated the safety and efficacy of a novel recombinant human interleukin-22 (IL-22) dimer in combination with systemic corticosteroids for the treatment of newly diagnosed gastrointestinal acute graft-versus-host disease (GVHD). The results showed that the overall response rate of the treatment group at day 28 was 70%.
Review
Biophysics
Mohamad Mohty, Florent Malard, Ahmed S. Alaskar, Mahmoud Aljurf, Mutlu Arat, Peter Bader, Frederic Baron, Ali Bazarbachi, Didier Blaise, Eolia Brissot, Fabio Ciceri, Selim Corbacioglu, Jean-Hugues Dalle, Fiona Dignan, Anne Huynh, Michelle Kenyon, Arnon Nagler, Antonio Pagliuca, Zinaida Peric, Paul G. Richardson, Annalisa Ruggeri, Tapani Ruutu, Ibrahim Yakoub-Agha, Rafael F. Duarte, Enric Carreras
Summary: Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can occur after hematopoietic cell transplantation (HCT). The European Society for Blood and Marrow Transplantation (EBMT) has recently updated the definition and severity grading system for SOS/VOD in adult patients. The aim of this work is to provide an update on the diagnosis, severity assessment, pathophysiology, and treatment of SOS/VOD in adult patients.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Arnon Nagler, Myriam Labopin, Ryszard Swoboda, Alexander Kulagin, Helene Labussiere-Wallet, Montserrat Rovira, Didier Blaise, Jan Vydra, Ibrahim Yakoub-Agha, Goda Choi, Peter Remenyi, Yener Koc, Jaime Sanz, Fabio Ciceri, Mohamad Mohty
Summary: Retrospective evaluation of transplant outcomes in adult AML patients undergoing allo-HCT in CR2 showed that post-transplant cyclophosphamide is an effective method for GVHD prophylaxis.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Frederic Baron, Annalisa Ruggeri, Christophe Peczynski, Myriam Labopin, Jean-Henri Bourhis, Mauricette Michallet, Patrice Chevallier, Jaime Sanz, Edouard Forcade, Riccardo Saccardi, Victoria Potter, Eliane Gluckman, Arnon Nagler, Mohamad Mohty
Summary: This study assessed the outcomes of patients who experienced graft failure after umbilical cord blood transplantation (CBT). It included a total of 87 patients and found that the cumulative incidence of relapse and nonrelapse mortality at 1-year was 35% and 37% respectively. Among patients who underwent salvage second transplantation, the 1-year and 2-year overall survival rates were 41% and 34% respectively. The study also identified complete remission and reduced-intensity conditioning as factors associated with better overall survival.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
M. A. de Witte, J. E. Mooyaart, J. D. Hoogenboom, C. Chabannon, F. Malard, A. Ruggeri, J. Kuball
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Arnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, Didier Blaise, Sergey Bondarenko, Jan Vydra, Goda Choi, Montserrat Rovira, Peter Remenyi, Ellen Meijer, Claude Eric Bulabois, J. L. Diez-Martin, Ibrahim Yakoub-Agha, Eolia Brissot, Alexandros Spyridonidis, Jaime Sanz, Amit Patel, Mutlu Arat, Ali Bazarbachi, Gesine Bug, Bipin N. Savani, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
Summary: In this study, the impact of measurable residual disease (MRD) on the outcomes of post-transplant cyclophosphamide (PTCy)-based allo-HCT in acute myeloid leukemia (AML) patients in first complete remission (CR1) was assessed. The results showed that MRD positive (MRD+) patients had higher relapse rates and lower survival rates compared to MRD negative (MRD-) patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Rama Al Hamed, Maud Ngoya, Jacques-Emmanuel Galimard, Henrik Sengeloev, Tobias Gedde-Dahl, Aleksandr Kulagin, Uwe Platzbecker, Ibrahim Yakoub-Agha, Jenny L. Byrne, Thomas Valerius, Gerard Socie, Nicolaus Kroeger, Didier Blaise, Ali Bazarbachi, Jaime Sanz, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: This retrospective study investigates the impact of time on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes for patients with acute myeloid leukemia (AML) in second complete remission (CR2). The results show that outcomes of allo-HCT in CR2 have significantly improved over time, with the most favorable outcomes achieved with a matched sibling donor (MSD).
Review
Oncology
Jean El-Cheikh, Nour Moukalled, Florent Malard, Ali Bazarbachi, Mohamad Mohty
Summary: With the improvement in cancer treatment, including multiple myeloma, the risk of cardiovascular disease in patients has significantly increased, especially in elderly patients and those with additional risk factors. The risk factors can be patient-, disease-, and/or therapy-related, and they impact survival negatively. About 7.5% of multiple myeloma patients experience cardiovascular events, with varied risks depending on patient characteristics and treatment used. Cardiac toxicities have been associated with immunomodulatory drugs, proteasome inhibitors, and other agents, highlighting the importance of comprehensive cardiac evaluation and surveillance strategies for early detection and management.
BLOOD CANCER JOURNAL
(2023)
Article
Biophysics
Tapani Ruutu, Christophe Peczynski, Mohamed Houhou, Emmanuelle Polge, Mohamad Mohty, Nicolaus Kroeger, Ivan Moiseev, Olaf Penack, Nina Salooja, Helene Schoemans, Rafael F. Duarte, Thomas Schroeder, Jakob Passweg, Gerald G. Wulf, Arnold Ganser, Simona Sica, Mutlu Arat, Urpu Salmenniemi, Annoek E. C. Broers, Jean Henri Bourhis, Alessandro Rambaldi, Johan Maertens, Kazimierz Halaburda, Tsila Zuckerman, Helene Labussiere-Wallet, Grzegorz Basak, Christian Koenecke, Zinaida Peric
Summary: The study investigated the incidence, diagnostic policy, management, and outcome of VOD/SOS at EBMT centers. It included 71 participating centers with a total of 2886 allogeneic transplantations and 93 cases of VOD/SOS in 2018. The findings showed a low incidence of VOD/SOS and a predominance of severe and very severe grades, indicating the importance of early diagnosis and treatment to improve outcomes.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
Giorgia Battipaglia, Jarl E. Mooyaart, Ralf Meyer, Mohamad Mohty, Alicja Sadowska-Klasa, Oleg Goloshchapov, Franco Locatelli, Jan Styczynski, Jiri Pavlu, Jaroslaw Dybko, Gleb Bronin, Urpu Salmenniemi, Pavel Jindra, Jorinde D. Hoogenboom, Jurgen Kuball, Annalisa Ruggeri, Florent Malard
BONE MARROW TRANSPLANTATION
(2023)